Expertise in
2
conditions

Dr. James H. Tarver

Florida Hospital Medical Group Inc
Orlando, FL
Expertise in
2
conditions
Specialties:Cardiology
Accepting New Patients
Offers Telehealth
Expertise in
2
conditions
OverviewInsuranceLocationsClinical Research

Overview

James Tarver is a Cardiologist in Orlando, Florida. MD. Tarver is highly rated in 2 conditions, according to our data. His top areas of expertise are Pulmonary Hypertension, Pulmonary Veno-Occlusive Disease, Systemic Sclerosis (SSc), and Hypertension. MD. Tarver is currently accepting new patients.

His clinical research consists of participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Cardiology
Licenses
Internal Medicine in FL
Hospital Affiliations
Adventhealth Orlando
Languages Spoken
English
Spanish
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Health First
  •  Health Options
  •  Oscar
  •  UnitedHealthcare
  •  Humana
View 1 More Insurance +

Locations

FLORIDA HOSPITAL MEDICAL GROUP INC
2501 N Orange Ave, Orlando, FL 32804
407-200-2700
Other Locations
FLORIDA HOSPITAL MEDICAL GROUP INC
2600 Westhall Ln, Fl 4, Maitland, FL 32751
407-200-2700
FLORIDA HOSPITAL MEDICAL GROUP INC
2100 Ocoee Apopka Rd, Apopka, FL 32703
FLORIDA HOSPITAL MEDICAL GROUP INC
601 E Rollins St, Orlando, FL 32803
407-303-2570

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

EXPEDITE: A 16-Week, Multicenter, Open-label Study of Remodulin Induction Followed by Orenitram Optimization in Subjects With Pulmonary Arterial Hypertension
EXPEDITE: A 16-Week, Multicenter, Open-label Study of Remodulin Induction Followed by Orenitram Optimization in Subjects With Pulmonary Arterial Hypertension
Enrollment Status: Completed
Publish Date: August 07, 2023
Intervention Type: Drug
Study Drug: Intravenous/Subcutaneous Treprostinil
Study Phase: Phase 4
A Randomized, Double-Blind, Parallel Group, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of Once Weekly Subcutaneous (SC) Injections of a Sustained-Release Vasoactive Intestinal Peptide (VIP) Analogue, Pemziviptadil (PB1046), in Adult Subjects With Symptomatic Pulmonary Arterial Hypertension (PAH)
A Randomized, Double-Blind, Parallel Group, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of Once Weekly Subcutaneous (SC) Injections of a Sustained-Release Vasoactive Intestinal Peptide (VIP) Analogue, Pemziviptadil (PB1046), in Adult Subjects With Symptomatic Pulmonary Arterial Hypertension (PAH)
Enrollment Status: Terminated
Publish Date: August 23, 2022
Intervention Type: Drug
Study Drug: Pemziviptadil
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
Enrollment Status: Completed
Publish Date: July 27, 2022
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
Enrollment Status: Terminated
Publish Date: November 10, 2020
Intervention Type: Drug
Study Phase: Phase 3
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
Enrollment Status: Terminated
Publish Date: October 22, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR added-on to Treprostinil, Inhaled (Tyvaso®) in Subjects With Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR added-on to Treprostinil, Inhaled (Tyvaso®) in Subjects With Pulmonary Arterial Hypertension
Enrollment Status: Completed
Publish Date: August 03, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 5 Less Clinical Trials
Similar Doctors
Sula E. Mazimba
Expertise in
16
conditions
Dr. Sula E. Mazimba
Advanced Heart Failure and Transplant Cardiology | Cardiology
Expertise in
16
conditions
Dr. Sula E. Mazimba
Advanced Heart Failure and Transplant Cardiology | Cardiology

Florida Hospital Medical Group Inc

601 E Rollins St, 
Orlando, FL 
 (0.2 mi)
407-303-2570
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sula Mazimba is an Advanced Heart Failure and Transplant Cardiologist and a Cardiologist in Orlando, Florida. Dr. Mazimba is highly rated in 16 conditions, according to our data. His top areas of expertise are Heart Failure, Pulmonary Hypertension, Pulmonary Edema, Heart Transplant, and Aortic Valve Replacement. Dr. Mazimba is currently accepting new patients.

Expertise in
28
conditions
Dr. Marwan M. Mihyu
Cardiology
Expertise in
28
conditions
Dr. Marwan M. Mihyu
Cardiology

Orlando Health Medical Group Inc

1414 Kuhl Ave, 
Orlando, FL 
 (3.4 mi)
407-841-5111
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Marwan Mihyu is a Cardiologist in Orlando, Florida. Dr. Mihyu is highly rated in 28 conditions, according to our data. His top areas of expertise are Atherosclerosis, Coronary Heart Disease, Angina, Pacemaker Implantation, and Endoscopy. Dr. Mihyu is currently accepting new patients.

Expertise in
27
conditions
Dr. Arnold M. Einhorn
Cardiology
Expertise in
27
conditions
Dr. Arnold M. Einhorn
Cardiology

Cardiovascular Institute Of Central Florida LLC

2859 Delaney Ave, Suite 100, 
Orlando, FL 
 (4.4 mi)
407-738-4200
Experience:
43+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Arnold Einhorn is a Cardiologist in Orlando, Florida. Dr. Einhorn has been practicing medicine for over 43 years is highly rated in 27 conditions, according to our data. His top areas of expertise are Coronary Heart Disease, Atherosclerosis, Angina, Familial Ventricular Tachycardia, and Cardiac Ablation. Dr. Einhorn is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile